Market Cap
US$6.2b
Last Updated
2021/07/24 23:29 UTC
Data Sources
Company Financials +
Executive Summary
Perrigo Company plc provides over-the-counter (OTC) health and wellness solutions that enhance individual well-being by empowering consumers to prevent or treat conditions that can be self-managed. More Details
Rewards
Risk Analysis
Snowflake Analysis
Excellent balance sheet and fair value.
Similar Companies
Share Price & News
How has Perrigo's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: PRGO is less volatile than 75% of US stocks over the past 3 months, typically moving +/- 3% a week.
Volatility Over Time: PRGO's weekly volatility (3%) has been stable over the past year.
Market Performance
7 Day Return
1.4%
PRGO
2.5%
US Pharmaceuticals
2.0%
US Market
1 Year Return
-17.0%
PRGO
17.7%
US Pharmaceuticals
39.1%
US Market
Return vs Industry: PRGO underperformed the US Pharmaceuticals industry which returned 17.7% over the past year.
Return vs Market: PRGO underperformed the US Market which returned 39.1% over the past year.
Shareholder returns
| PRGO | Industry | Market | |
|---|---|---|---|
| 7 Day | 1.4% | 2.5% | 2.0% |
| 30 Day | 0.2% | 3.6% | 1.6% |
| 90 Day | 10.8% | 7.2% | 3.5% |
| 1 Year | -15.3%-17.0% | 22.6%17.7% | 41.3%39.1% |
| 3 Year | -37.9%-41.0% | 35.5%24.2% | 64.0%53.8% |
| 5 Year | -45.8%-49.3% | 46.6%27.6% | 123.9%99.0% |
Long-Term Price Volatility Vs. Market
How volatile is Perrigo's share price compared to the market and industry in the last 5 years?
Simply Wall St News
1 week ago | Simply Wall St
Here's Why Perrigo (NYSE:PRGO) Has A Meaningful Debt Burden1 month ago | Simply Wall St
Are Investors Undervaluing Perrigo Company plc (NYSE:PRGO) By 44%?1 month ago | Simply Wall St
Read This Before Considering Perrigo Company plc (NYSE:PRGO) For Its Upcoming US$0.24 DividendValuation
Is Perrigo undervalued compared to its fair value and its price relative to the market?
43.7%
Undervalued compared to fair value
Share Price vs. Fair Value
Below Fair Value: PRGO ($46.34) is trading below our estimate of fair value ($82.32)
Significantly Below Fair Value: PRGO is trading below fair value by more than 20%.
Price To Earnings Ratio
PE vs Industry: PRGO is unprofitable, so we can't compare its PE Ratio to the US Pharmaceuticals industry average.
PE vs Market: PRGO is unprofitable, so we can't compare its PE Ratio to the US market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate PRGO's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: PRGO is good value based on its PB Ratio (1.1x) compared to the US Pharmaceuticals industry average (3x).
Future Growth
How is Perrigo forecast to perform in the next 1 to 3 years based on estimates from 6 analysts?
114.8%
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: PRGO is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (2%).
Earnings vs Market: PRGO is forecast to become profitable over the next 3 years, which is considered above average market growth.
High Growth Earnings: PRGO's is expected to become profitable in the next 3 years.
Revenue vs Market: PRGO's revenue (1.6% per year) is forecast to grow slower than the US market (9.3% per year).
High Growth Revenue: PRGO's revenue (1.6% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if PRGO's Return on Equity is forecast to be high in 3 years time
Past Performance
How has Perrigo performed over the past 5 years?
63.3%
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: PRGO is currently unprofitable.
Growing Profit Margin: PRGO is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: PRGO is unprofitable, but has reduced losses over the past 5 years at a rate of 63.3% per year.
Accelerating Growth: Unable to compare PRGO's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: PRGO is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (10.1%).
Return on Equity
High ROE: PRGO has a negative Return on Equity (-3.91%), as it is currently unprofitable.
Financial Health
How is Perrigo's financial position?
Financial Position Analysis
Short Term Liabilities: PRGO's short term assets ($4.5B) exceed its short term liabilities ($1.4B).
Long Term Liabilities: PRGO's short term assets ($4.5B) exceed its long term liabilities ($4.3B).
Debt to Equity History and Analysis
Debt Level: PRGO's debt to equity ratio (63.5%) is considered high.
Reducing Debt: PRGO's debt to equity ratio has reduced from 67.5% to 63.5% over the past 5 years.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: Whilst unprofitable PRGO has sufficient cash runway for more than 3 years if it maintains its current positive free cash flow level.
Forecast Cash Runway: PRGO is unprofitable but has sufficient cash runway for more than 3 years, even with free cash flow being positive and shrinking by 24.4% per year.
Dividend
What is Perrigo current dividend yield, its reliability and sustainability?
2.07%
Current Dividend Yield
Dividend Yield vs Market
Notable Dividend: PRGO's dividend (2.07%) is higher than the bottom 25% of dividend payers in the US market (1.32%).
High Dividend: PRGO's dividend (2.07%) is low compared to the top 25% of dividend payers in the US market (3.56%).
Stability and Growth of Payments
Stable Dividend: PRGO's dividends per share have been stable in the past 10 years.
Growing Dividend: PRGO's dividend payments have increased over the past 10 years.
Current Payout to Shareholders
Dividend Coverage: PRGO is paying a dividend but the company is unprofitable.
Future Payout to Shareholders
Future Dividend Coverage: Insufficient data to determine if a dividend will be paid in 3 years and that it will be covered by earnings.
Next Steps
Management
How experienced are the management team and are they aligned to shareholders interests?
4.4yrs
Average management tenure
CEO
Murray Kessler (61 yo)
2.75yrs
Tenure
US$10,967,230
Compensation
Mr. Murray S. Kessler has been the Chief Executive Officer, President and Director of Perrigo Company plc since October 8, 2018. Mr. Kessler has more years of leadership experience in growing consumer prod...
CEO Compensation Analysis
Compensation vs Market: Murray's total compensation ($USD10.97M) is above average for companies of similar size in the US market ($USD6.50M).
Compensation vs Earnings: Murray's compensation has increased whilst the company is unprofitable.
Leadership Team
Experienced Management: PRGO's management team is considered experienced (4.4 years average tenure).
Board Members
Experienced Board: PRGO's board of directors are considered experienced (4.2 years average tenure).
Ownership
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Ownership Breakdown
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Top Shareholders
Company Information
Perrigo Company plc's company bio, employee growth, exchange listings and data sources
Key Information
- Name: Perrigo Company plc
- Ticker: PRGO
- Exchange: NYSE
- Founded: 1887
- Industry: Pharmaceuticals
- Sector: Pharmaceuticals & Biotech
- Market Cap: US$6.189b
- Shares outstanding: 133.55m
- Website: https://www.perrigo.com
Number of Employees
Location
- Perrigo Company plc
- The Sharp Building
- Hogan Place
- Dublin
- Co. Dublin
- 2
- Ireland
Listings
Biography
Perrigo Company plc provides over-the-counter (OTC) health and wellness solutions that enhance individual well-being by empowering consumers to prevent or treat conditions that can be self-managed. The com...
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2021/07/24 23:29 |
| End of Day Share Price | 2021/07/23 00:00 |
| Earnings | 2021/04/03 |
| Annual Earnings | 2020/12/31 |
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.